PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?

Geburtshilfe und Frauenheilkunde
Maria Luisa GasparriPierluigi Benedetti Panici

Abstract

The high recurrence rate and the low overall survival in ovarian cancer suggest that a more specific therapeutic approach in addition to conventional treatment is required. Translational and clinical research is investigating new molecular targets in order to find an alternative way to affect tumor growth and to minimize the overlap of toxicity of antiblastic agents. Given its implication in many cellular activities including regulation of cell growth, motility, survival, proliferation, protein synthesis, autophagy, transcription, as well as angiogenesis, PI3K/AKT/mTOR is one of the most investigated intracellular signaling pathways. A dis-regulation of this pathway has been shown in several tumors, including ovarian cancer. In this setting, mTor proteins represent a potential target for inhibitors, which could ultimately play a pivotal role in counteracting cellular proliferation. Recently, mTor inhibitors have been approved in the treatment of pancreatic neuroendocrine tumors, mantle cell lymphoma and renal cancer. Clinical trials have assessed the safety of these drugs in ovarian cancer patients. Ongoing phase I and II studies are evaluating the oncologic outcome of mTor inhibitor treatment and its effect in combination with...Continue Reading

Citations

Sep 25, 2019·Cancers·Periklis KatopodisEmmanouil Karteris
Aug 16, 2018·Journal of Cancer Research and Clinical Oncology·Maria Luisa GasparriElisabetta Ferretti
Dec 4, 2019·International Journal of Oncology·Mingxi XuZhong Wang
Mar 15, 2019·Experimental and Therapeutic Medicine·Yiyun Tan, Lei Liu
Oct 13, 2020·Naunyn-Schmiedeberg's Archives of Pharmacology·Yanting ZhuDaohua Shi
Sep 25, 2019·The International Journal of Biochemistry & Cell Biology·Lingling GaoBei Lin
Oct 23, 2020·Pharmacology & Therapeutics·Martina ChiacchiariniElisabetta Ferretti
Apr 3, 2021·Cancer Cell International·Zeeshan JavedJavad Sharifi-Rad
Sep 25, 2020·Asia-Pacific Journal of Clinical Oncology·Rana Muhammad UsmanFaiz Anwer
May 10, 2020·Cellular Oncology (Dordrecht)·Yangjiong XiaoRong Zhang
Apr 2, 2021·Biochemical Pharmacology·Jing ZhaoShuhua Zhao
Jun 25, 2021·Journal of Ovarian Research·Huixi WengZhiqun Zheng
Jul 20, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry· IksenVarisa Pongrakhananon
Aug 7, 2021·Biomolecules·Chao-Lien LiuTsui-Lien Mao
Aug 28, 2021·Biomedicines·Santosh Kumar SinghRajesh Singh
Oct 25, 2021·Cancer Science·Hoshino DaisukeNaohiko Koshikawa

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01031381
NCT02188550
NCT02283658
NCT00886691
NCT01281514
NCT00982631
NCT01460979
NCT01196429
NCT01010126
NCT01065662

Related Concepts

Related Feeds

Adenoma, Islet Cell

Islet Cell Adenoma arises in the islet cells, which are insulin producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Adenoma here.

Carcinoma, Islet Cell (Keystone)

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arise in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on islet cell carcinoma in this feed.

Autophagy & Model Organisms

Autophagy is a cellular process that allows degradation by the lysosome of cytoplasmic components such as proteins or organelles. Here is the latest research on autophagy & model organisms

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Carcinoma, Islet Cell

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arises in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Carcinoma here.